Imke M. E. Schuurmans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Imke M. E. Schuurmans has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Nael Nadif Kasri
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
7 shared publications - Annika Mordelt
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publications - Marina P. Hommersom
Department of Human Genetics Radboud university medical center Nijmegen The Netherlands
4 shared publications - Alejandro Garanto
Department of Pediatrics, Radboud University Medical Center, Amalia Children’s Hospital, Nijmegen, The Netherlands
3 shared publications Astrid Oudakker
Department of Human Genetics Radboud university medical center Nijmegen The Netherlands
3 shared publications- Clara D. M. van Karnebeek
Emma Center for Personalized Medicine, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Human Genetics, Amsterdam Reproduction & Development, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Pediatrics, Amsterdam University Medical Center, Emma Children's Hospital, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; United for Metabolic Diseases, Amsterdam, the Netherlands
3 shared publications
Latest Publications
- Open Access
Navigating Human Astrocyte Differentiation: Direct and Rapid One‐Step Differentiation of Induced Pluripotent Stem Cells to Functional Astrocytes Supporting Neuronal Network Development
Astrocytes play a pivotal role in neuronal network development. Despite the well‐known role of astrocytes in the pathophysiology of neurologic disorders, the utilization of induced pluripotent stem cell (iPSC)‐derived astrocytes in neuronal networks remains limited. Here, we present a streamlined one‐step protocol for the differentiation of iPSCs directly into functional astrocytes without the need for ectopic gene expression or neural progenitor cell generation. We found that culturing iPSCs directly in commercial astrocyte medium, was sufficient to differentiate iPSCs into functional astrocytes within 5 weeks. More than 60 iPSC lines were successfully differentiated into astrocytes by independent researchers across 10 independent laboratories. Validation of the iPSC‐astrocyte cultures demonstrated consistent astrocyte differentiation with minimal batch‐to‐batch variability. In dept. characterization of a subset of iPSC lines confirmed astrocyte identity and functionality of the iPSC‐astrocyte monocultures by immunofluorescence, flow cytometry, RNA sequencing, glutamate uptake assays and calcium signaling recordings. Optimization of the protocol enabled co‐culture of iPSC‐astrocytes with Ngn2 iPSC‐derived neurons (iNeurons), promoting neuronal differentiation and synapse formation. Lastly, we used single‐cell electrophysiology and multi‐electrode arrays, by four independent researchers, to confirm robust neuronal network development in 5‐week‐old iPSC‐astrocyte and iNeuron co‐cultures. This protocol offers a rapid and efficient method to establish all‐human astrocyte‐neuron co‐cultures, facilitating the investigation of cell‐type‐specific contributions to disease pathogenesis. Its validation across numerous iPSC lines in 10 independent laboratories highlights the reproducibility of the protocol and positions it as a platform for advancing disease modeling in human neural networks.
Open AccessNavigating Human Astrocyte Differentiation: Direct and Rapid One‐Step Differentiation of Induced Pluripotent Stem Cells to Functional Astrocytes Supporting Neuronal Network Development
Astrocytes play a pivotal role in neuronal network development. Despite the well‐known role of astrocytes in the pathophysiology of neurologic disorders, the utilization of induced pluripotent stem cell (iPSC)‐derived astrocytes in neuronal networks remains limited. Here, we present a streamlined one‐step protocol for the differentiation of iPSCs directly into functional astrocytes without the need for ectopic gene expression or neural progenitor cell generation. We found that culturing iPSCs directly in commercial astrocyte medium, was sufficient to differentiate iPSCs into functional astrocytes within 5 weeks. More than 60 iPSC lines were successfully differentiated into astrocytes by independent researchers across 10 independent laboratories. Validation of the iPSC‐astrocyte cultures demonstrated consistent astrocyte differentiation with minimal batch‐to‐batch variability. In dept. characterization of a subset of iPSC lines confirmed astrocyte identity and functionality of the iPSC‐astrocyte monocultures by immunofluorescence, flow cytometry, RNA sequencing, glutamate uptake assays and calcium signaling recordings. Optimization of the protocol enabled co‐culture of iPSC‐astrocytes with Ngn2 iPSC‐derived neurons (iNeurons), promoting neuronal differentiation and synapse formation. Lastly, we used single‐cell electrophysiology and multi‐electrode arrays, by four independent researchers, to confirm robust neuronal network development in 5‐week‐old iPSC‐astrocyte and iNeuron co‐cultures. This protocol offers a rapid and efficient method to establish all‐human astrocyte‐neuron co‐cultures, facilitating the investigation of cell‐type‐specific contributions to disease pathogenesis. Its validation across numerous iPSC lines in 10 independent laboratories highlights the reproducibility of the protocol and positions it as a platform for advancing disease modeling in human neural networks.
- Open Access
MEA-LINK identifies the CCL4-CCR5 axis in neuronal hyperactivity control by human microglia
Microglia, the resident immune cells of the brain, act along a spectrum to maintain CNS homeostasis, respond to perturbations, and control neuronal activity. Disentangling the molecular mechanisms of human microglia-neuron crosstalk remains challenging due to the context-dependent, dynamic nature of their interaction. We introduce MEA-LINK, a systems-approach leveraging natural variation to screen for immune modulators of neuronal activity. This multi-modal platform integrates human induced pluripotent stem cell (hiPSC) technology with micro-electrode array (MEA) recordings and proteomic analyses of secreted immune factors, allowing for longitudinal samples and correlations across modalities. We applied MEA-LINK to explore microglia-neuron interactions during development and hyperactivity challenges. We show that human microglia accelerate neuronal network development and rescue hyperactive network phenotypes. Linking the secretome adaptations to neuronal network activity variations, we identified CCL4 as a top candidate in microglia-mediated hyperactivity control. Then, we functionally validated the context-dependent role of microglial CCL4 to neuronal CCR5 signaling in human neuronal networks. Our findings support a neuron-specific function of chemokines and their receptors in the brain and provide a new perspective for immune signaling in neuronal hyperactivity control. The MEA-LINK platform thus offers a foundation for comprehensive, systematic studies of human microglia-neuron interactions. Highlights: MEA-LINK integrates micro-electrode array recordings with proteomics of longitudinal samples to identify immune modulators of neuronal activity. Human microglia rescue neuronal hyperactivity induced by pharmacological and genetic challenges. Microglial CCL4 dampens neuronal activity via CCR5 signaling in a context-dependent manner. Graphical
Open AccessMEA-LINK identifies the CCL4-CCR5 axis in neuronal hyperactivity control by human microglia
Microglia, the resident immune cells of the brain, act along a spectrum to maintain CNS homeostasis, respond to perturbations, and control neuronal activity. Disentangling the molecular mechanisms of human microglia-neuron crosstalk remains challenging due to the context-dependent, dynamic nature of their interaction. We introduce MEA-LINK, a systems-approach leveraging natural variation to screen for immune modulators of neuronal activity. This multi-modal platform integrates human induced pluripotent stem cell (hiPSC) technology with micro-electrode array (MEA) recordings and proteomic analyses of secreted immune factors, allowing for longitudinal samples and correlations across modalities. We applied MEA-LINK to explore microglia-neuron interactions during development and hyperactivity challenges. We show that human microglia accelerate neuronal network development and rescue hyperactive network phenotypes. Linking the secretome adaptations to neuronal network activity variations, we identified CCL4 as a top candidate in microglia-mediated hyperactivity control. Then, we functionally validated the context-dependent role of microglial CCL4 to neuronal CCR5 signaling in human neuronal networks. Our findings support a neuron-specific function of chemokines and their receptors in the brain and provide a new perspective for immune signaling in neuronal hyperactivity control. The MEA-LINK platform thus offers a foundation for comprehensive, systematic studies of human microglia-neuron interactions. Highlights: MEA-LINK integrates micro-electrode array recordings with proteomics of longitudinal samples to identify immune modulators of neuronal activity. Human microglia rescue neuronal hyperactivity induced by pharmacological and genetic challenges. Microglial CCL4 dampens neuronal activity via CCR5 signaling in a context-dependent manner. Graphical
- Open Access
Mapping NMD-coupled alternative splicing in iPSC-derived brain cells: a resource for therapeutic discovery
Therapeutic options for neurodevelopmental disorders (NDD) are expanding. Targeting alternative splicing (AS) events linked to nonsense-mediated decay (NMD) offers a promising way to boost gene expression in haploinsufficiency disorders. However, naturally occurring NMD-coupled AS (NMD AS) events in brain cells remain poorly characterized. Here, we integrate long- and short-read RNA sequencing of NMD-inhibited induced pluripotent stem cell-derived excitatory neurons, astrocytes, and microglia to map and prioritize NMD AS events most suitable for therapeutic intervention. We developed an optimized prediction framework and provide an open access, queryable, database cataloging the existence and abundance of NMD AS events across these cell types. Querying this resource, we identified 936 NMD-sensitive AS events in 250 autosomal-dominant NDD genes and nominate 60 NMD AS events in haploinsufficient genes underlying 42 NDDs that are abundant in at least one cell type and thus represent promising therapeutic targets. These included a previously targeted NMD AS event in SCN1A , and known NMD AS events in CHD2, EZH2, and NR4A2 , for which we confirm high cell type-specific abundance, as well as an newly identified abundant event in PHIP . Beyond NDD genes, we identify 1,817 differentially spliced AS events including NMD AS events, highlighting the potential functional role of (NMD) AS within brain cell-specific regulatory programs. This framework and resource enables systematic discovery and prioritization of therapeutically targetable NMD AS events and establish a cell-type resolved atlas to guide splice-modulating strategies in NDDs.
Open AccessMapping NMD-coupled alternative splicing in iPSC-derived brain cells: a resource for therapeutic discovery
Therapeutic options for neurodevelopmental disorders (NDD) are expanding. Targeting alternative splicing (AS) events linked to nonsense-mediated decay (NMD) offers a promising way to boost gene expression in haploinsufficiency disorders. However, naturally occurring NMD-coupled AS (NMD AS) events in brain cells remain poorly characterized. Here, we integrate long- and short-read RNA sequencing of NMD-inhibited induced pluripotent stem cell-derived excitatory neurons, astrocytes, and microglia to map and prioritize NMD AS events most suitable for therapeutic intervention. We developed an optimized prediction framework and provide an open access, queryable, database cataloging the existence and abundance of NMD AS events across these cell types. Querying this resource, we identified 936 NMD-sensitive AS events in 250 autosomal-dominant NDD genes and nominate 60 NMD AS events in haploinsufficient genes underlying 42 NDDs that are abundant in at least one cell type and thus represent promising therapeutic targets. These included a previously targeted NMD AS event in SCN1A , and known NMD AS events in CHD2, EZH2, and NR4A2 , for which we confirm high cell type-specific abundance, as well as an newly identified abundant event in PHIP . Beyond NDD genes, we identify 1,817 differentially spliced AS events including NMD AS events, highlighting the potential functional role of (NMD) AS within brain cell-specific regulatory programs. This framework and resource enables systematic discovery and prioritization of therapeutically targetable NMD AS events and establish a cell-type resolved atlas to guide splice-modulating strategies in NDDs.
- Open Access
Long-term co-maturation of stem cell-derived microglia and neuronal networks: an optimized platform to assess human microglial contribution to neuronal function
Microglia-neuron interactions play a central role in a variety of central nervous system disorders. Technologies using human induced pluripotent stem cells (hiPSCs) have been developed to model human brain cells with the goal to understand their function. To effectively study neuro-immune crosstalk and investigate microglial contributions to neuronal network development and function, both microglia and neurons should co-mature allowing for long-term interactions throughout their differentiation. Here, we present a co-maturation protocol that robustly generates glutamatergic neuronal networks containing human iPSC-derived microglia. We validated the long-term co-cultures using single-cell transcriptomics, imaging and neuronal activity readouts. We show that astrocytes were required for long-term survival of microglia and for their integration into neuronal networks. Our co-maturation approach induced the typical ramified microglia morphology and characteristic microglia-neuron interactions. Homeostatic markers like P2RY12 and TMEM119 and neuronal remodeling associated genes were upregulated compared to microglia monocultures, highlighting the necessity of the environment to generate and maintain the context-dependent microglia signature in vitro. In this manuscript, we include the full optimization process of our co-maturation approach, a comprehensive description of the protocol, practical guidelines and troubleshooting tips. Our co-maturation model provides a powerful tool to assess the role of human microglia in modulating neuronal function and development in health and disease. Highlights: ptimized human iPSC differentiation protocol that allows for co-maturation of microglia and Neurogenin2 -induced neuronal networks. are required for long-term survival and integration of microglia into neuronal networks. Co-maturation approach enables characteristic neuron-microglia interactions and induces signature morphology, transcriptome and proteins of human microglia.
Open AccessLong-term co-maturation of stem cell-derived microglia and neuronal networks: an optimized platform to assess human microglial contribution to neuronal function
Microglia-neuron interactions play a central role in a variety of central nervous system disorders. Technologies using human induced pluripotent stem cells (hiPSCs) have been developed to model human brain cells with the goal to understand their function. To effectively study neuro-immune crosstalk and investigate microglial contributions to neuronal network development and function, both microglia and neurons should co-mature allowing for long-term interactions throughout their differentiation. Here, we present a co-maturation protocol that robustly generates glutamatergic neuronal networks containing human iPSC-derived microglia. We validated the long-term co-cultures using single-cell transcriptomics, imaging and neuronal activity readouts. We show that astrocytes were required for long-term survival of microglia and for their integration into neuronal networks. Our co-maturation approach induced the typical ramified microglia morphology and characteristic microglia-neuron interactions. Homeostatic markers like P2RY12 and TMEM119 and neuronal remodeling associated genes were upregulated compared to microglia monocultures, highlighting the necessity of the environment to generate and maintain the context-dependent microglia signature in vitro. In this manuscript, we include the full optimization process of our co-maturation approach, a comprehensive description of the protocol, practical guidelines and troubleshooting tips. Our co-maturation model provides a powerful tool to assess the role of human microglia in modulating neuronal function and development in health and disease. Highlights: ptimized human iPSC differentiation protocol that allows for co-maturation of microglia and Neurogenin2 -induced neuronal networks. are required for long-term survival and integration of microglia into neuronal networks. Co-maturation approach enables characteristic neuron-microglia interactions and induces signature morphology, transcriptome and proteins of human microglia.
- Open Access
Targeting AASS improves neurotoxicity and mitochondrial function in astrocyte models for pyridoxine dependent epilepsy
Pyridoxine-dependent epilepsy (PDE) is a rare neurometabolic disorder of lysine catabolism caused by bi-allelic variants in ALDH7A1 . This enzyme deficiency leads to the accumulation of neurotoxic metabolites, pyridoxal-phosphate inactivation and consequently severe neurological symptoms. Current treatments, including vitamin B6 supplementation and lysine-restricted diets, partially alleviate seizures and intellectual disability but are not curative. To explore underlying mechanisms and potential therapies, we generated patient-derived human induced pluripotent stem lines (hiPSC) that were subsequently differentiated into astrocytes, the primary source of ALDH7A1 in the brain and key regulators of metabolic homeostasis. Metabolomic analyses confirmed elevated PDE biomarkers, and RNA sequencing revealed gene expression changes consistent with increased oxidative stress. Oxidative damage was validated by markers of DNA oxidation and lipid peroxidation. In addition, dysregulated oxygen consumption rates suggested mitochondrial dysfunction in PDE astrocytes. Notably, these pathological phenotypes were alleviated by downregulating AASS , the first enzyme of the lysine catabolism, by using CRISPR/Cas9 editing or antisense oligonucleotides (AON). This demonstrates that lysine catabolism underlies these phenotypes and highlights the therapeutic potential of AON therapy targeting AASS to reduce neurotoxic metabolite accumulation. These findings provide a promising strategy for developing targeted treatments for PDE and other rare neurometabolic disorders.
Open AccessTargeting AASS improves neurotoxicity and mitochondrial function in astrocyte models for pyridoxine dependent epilepsy
Pyridoxine-dependent epilepsy (PDE) is a rare neurometabolic disorder of lysine catabolism caused by bi-allelic variants in ALDH7A1 . This enzyme deficiency leads to the accumulation of neurotoxic metabolites, pyridoxal-phosphate inactivation and consequently severe neurological symptoms. Current treatments, including vitamin B6 supplementation and lysine-restricted diets, partially alleviate seizures and intellectual disability but are not curative. To explore underlying mechanisms and potential therapies, we generated patient-derived human induced pluripotent stem lines (hiPSC) that were subsequently differentiated into astrocytes, the primary source of ALDH7A1 in the brain and key regulators of metabolic homeostasis. Metabolomic analyses confirmed elevated PDE biomarkers, and RNA sequencing revealed gene expression changes consistent with increased oxidative stress. Oxidative damage was validated by markers of DNA oxidation and lipid peroxidation. In addition, dysregulated oxygen consumption rates suggested mitochondrial dysfunction in PDE astrocytes. Notably, these pathological phenotypes were alleviated by downregulating AASS , the first enzyme of the lysine catabolism, by using CRISPR/Cas9 editing or antisense oligonucleotides (AON). This demonstrates that lysine catabolism underlies these phenotypes and highlights the therapeutic potential of AON therapy targeting AASS to reduce neurotoxic metabolite accumulation. These findings provide a promising strategy for developing targeted treatments for PDE and other rare neurometabolic disorders.
- Open Access
Neuronal autophagosomes are transported to astrocytes for degradation
Autophagy is a vital catabolic process responsible for the degradation of cytosolic components, playing a key role in cellular homeostasis and survival. At synapses, autophagy is crucial for regulating neuronal activity and utilizes a specialized machinery. While considerable progress has been made in understanding the initiation of autophagy and autophagosome formation, the mechanisms governing the clearance of autophagosomes from synaptic sites remain poorly understood. Here, we identify a novel pathway in which astrocytes actively participate in the clearance of pre-synaptic autophagosomes. Using neurons derived from human induced pluripotent stem cell (hiPSC) lines expressing fluorescent autophagy markers and chimeric mouse models, we demonstrate that neuronal autophagosomal vesicles are physically transferred to astrocytes, a process that is enhanced when synaptic activity is suppressed. Autophagosome transfer does not require direct physical cellular contact, but it does require Dynamin and cholesterol-dependent endocytosis for the internalized neuronal autophagosomes to ultimately fuse with astrocytic lysosomes. Our findings reveal a previously unrecognized mechanism of neuronal autophagosome clearance that does not require slow axonal retrograde transport but their transfer to nearby astrocytes.
Open AccessNeuronal autophagosomes are transported to astrocytes for degradation
Autophagy is a vital catabolic process responsible for the degradation of cytosolic components, playing a key role in cellular homeostasis and survival. At synapses, autophagy is crucial for regulating neuronal activity and utilizes a specialized machinery. While considerable progress has been made in understanding the initiation of autophagy and autophagosome formation, the mechanisms governing the clearance of autophagosomes from synaptic sites remain poorly understood. Here, we identify a novel pathway in which astrocytes actively participate in the clearance of pre-synaptic autophagosomes. Using neurons derived from human induced pluripotent stem cell (hiPSC) lines expressing fluorescent autophagy markers and chimeric mouse models, we demonstrate that neuronal autophagosomal vesicles are physically transferred to astrocytes, a process that is enhanced when synaptic activity is suppressed. Autophagosome transfer does not require direct physical cellular contact, but it does require Dynamin and cholesterol-dependent endocytosis for the internalized neuronal autophagosomes to ultimately fuse with astrocytic lysosomes. Our findings reveal a previously unrecognized mechanism of neuronal autophagosome clearance that does not require slow axonal retrograde transport but their transfer to nearby astrocytes.
- Open Access
Navigating Human Astrocyte Differentiation: Direct and Rapid one-step Differentiation of Induced Pluripotent Stem Cells to Functional Astrocytes Supporting Neuronal Network development
Astrocytes play a pivotal role in neuronal network development. Despite the well-known role of astrocytes in the pathophysiology of neurologic disorders, the utilization of human induced pluripotent stem cell (hiPSC)-derived astrocytes in neuronal networks remains limited. Here, we present a streamlined one-step protocol for the differentiation of hiPSCs directly into functional astrocytes without the need for ectopic gene expression or neural progenitor cell generation. We found that culturing hiPSCs directly in commercial astrocyte medium, was sufficient to differentiate hiPSCs into functional astrocytes within five weeks. Validation to varying extents across thirty hiPSC-lines demonstrated consistent astrocyte differentiation with minimal batch-to-batch variability. We confirmed astrocyte identity and functionality of the hiPSC-astrocyte monocultures by immunofluorescence, flowcytometry, RNA sequencing, glutamate uptake assays and calcium signaling recordings. Optimization of the protocol enabled co-culture of hiPSC-astrocytes with Ngn2 hiPSC-derived neurons (iNeurons), promoting neuronal differentiation and synapse formation. Lastly, we used single-cell electrophysiology and multi-electrode arrays to confirm robust neuronal network development in 5-week-old hiPSC-astrocyte and iNeuron co-cultures. This protocol offers a rapid and efficient method to establish all-human astrocyte-neuron co-cultures, facilitating the investigation of cell-type-specific contributions to disease pathogenesis. While validated across multiple hiPSC lines, we actively encourage researchers to test and provide feedback on this protocol to enhance its validation for future iterations.
Open AccessNavigating Human Astrocyte Differentiation: Direct and Rapid one-step Differentiation of Induced Pluripotent Stem Cells to Functional Astrocytes Supporting Neuronal Network development
Astrocytes play a pivotal role in neuronal network development. Despite the well-known role of astrocytes in the pathophysiology of neurologic disorders, the utilization of human induced pluripotent stem cell (hiPSC)-derived astrocytes in neuronal networks remains limited. Here, we present a streamlined one-step protocol for the differentiation of hiPSCs directly into functional astrocytes without the need for ectopic gene expression or neural progenitor cell generation. We found that culturing hiPSCs directly in commercial astrocyte medium, was sufficient to differentiate hiPSCs into functional astrocytes within five weeks. Validation to varying extents across thirty hiPSC-lines demonstrated consistent astrocyte differentiation with minimal batch-to-batch variability. We confirmed astrocyte identity and functionality of the hiPSC-astrocyte monocultures by immunofluorescence, flowcytometry, RNA sequencing, glutamate uptake assays and calcium signaling recordings. Optimization of the protocol enabled co-culture of hiPSC-astrocytes with Ngn2 hiPSC-derived neurons (iNeurons), promoting neuronal differentiation and synapse formation. Lastly, we used single-cell electrophysiology and multi-electrode arrays to confirm robust neuronal network development in 5-week-old hiPSC-astrocyte and iNeuron co-cultures. This protocol offers a rapid and efficient method to establish all-human astrocyte-neuron co-cultures, facilitating the investigation of cell-type-specific contributions to disease pathogenesis. While validated across multiple hiPSC lines, we actively encourage researchers to test and provide feedback on this protocol to enhance its validation for future iterations.
- Open Access
- 16 April 2023
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 46 (3) , 371-390
Exploring genotype–phenotype correlations in glutaric aciduria type 1
Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH). We performed an extensive literature search to collect data on GA1 patients, together with unpublished cases, to provide an up‐to‐date genetic landscape of GCDH pathogenic variants and to investigate potential genotype‐phenotype correlation, as this is still poorly understood. From this search, 421 different GCDH pathogenic variants have been identified, including four novel variants; c.179T>C (p.Leu60Pro), c.214C>T (p.Arg72Cys), c.309G>C (p.Leu103Phe), and c.665T>C (p.Phe222Ser).The variants are mostly distributed across the entire gene; although variant frequency in GA1 patients is relatively high in the regions encoding for active domains of GCDH. To investigate potential genotype‐phenotype correlations, phenotypic descriptions of 532 patients have been combined and evaluated using novel combinatorial analyses. To do so, various clinical phenotypes were determined for each pathogenic variant by combining the information of all GA1 patients reported with this pathogenic variant, and subsequently mapped onto the 2D and 3D GCDH protein structure. In addition, the predicted pathogenicity of missense variants was analyzed using different in silico prediction score models. Both analyses showed an almost similar distribution of the highly pathogenic variants across the GCDH protein, although some hotspots, including the active domain, were observed. Moreover, it was demonstrated that highly pathogenic variants are significantly correlated with lower residual enzyme activity and the most accurate estimation was achieved by the REVEL score. A clear correlation of the genotype and the clinical phenotype however is still lacking.
- 16 April 2023
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 46 (3) , 371-390
Open AccessExploring genotype–phenotype correlations in glutaric aciduria type 1
Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH). We performed an extensive literature search to collect data on GA1 patients, together with unpublished cases, to provide an up‐to‐date genetic landscape of GCDH pathogenic variants and to investigate potential genotype‐phenotype correlation, as this is still poorly understood. From this search, 421 different GCDH pathogenic variants have been identified, including four novel variants; c.179T>C (p.Leu60Pro), c.214C>T (p.Arg72Cys), c.309G>C (p.Leu103Phe), and c.665T>C (p.Phe222Ser).The variants are mostly distributed across the entire gene; although variant frequency in GA1 patients is relatively high in the regions encoding for active domains of GCDH. To investigate potential genotype‐phenotype correlations, phenotypic descriptions of 532 patients have been combined and evaluated using novel combinatorial analyses. To do so, various clinical phenotypes were determined for each pathogenic variant by combining the information of all GA1 patients reported with this pathogenic variant, and subsequently mapped onto the 2D and 3D GCDH protein structure. In addition, the predicted pathogenicity of missense variants was analyzed using different in silico prediction score models. Both analyses showed an almost similar distribution of the highly pathogenic variants across the GCDH protein, although some hotspots, including the active domain, were observed. Moreover, it was demonstrated that highly pathogenic variants are significantly correlated with lower residual enzyme activity and the most accurate estimation was achieved by the REVEL score. A clear correlation of the genotype and the clinical phenotype however is still lacking.